 Oncternal Therapeutics, Inc. Nasdaq: ONCT, a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced an interim clinical data update for cirmtuzumab, a ROR1-targeted monoclonal antibody, combined with ibrutinib, in patients with relapsedrefractory mantle cell lymphoma MCL as part of the ongoing Phase 12 CIRLL Cirmtuzumab and Ibrutinib targeting ROR1 for Leukemia and Lymphoma clinical trial data cutoff as of March 6, 2020: 